Vincristine liposome

Vincristine liposome
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING See full prescribing information for complete Boxed Warning. For Intravenous Use Only – Fatal if Given by Other Routes . Death has occurred with intrathecal administration. vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose prior to preparation and administration to avoid overdosage.

Overview

Vincristine liposome is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Adult ALL in Second or Greater Relapse

• vincristine sulfate ® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate. Clinical benefit such as improvement in overall survival has not been verified.

• For Intravenous Use Only. Fatal if Given by Other Routes.
• vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vincristine sulfate injection. Verify drug name and dose prior to preparation and administration to avoid overdosage.

Recommended Dosage

• The recommended dose of vincristine sulfate is 2.25 mg/m2 intravenously over 1 hour once every 7 days.

• vincristine sulfate is liposome-encapsulated vincristine.

Dose modifications: Peripheral Neuropathy

• vincristine sulfate is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome [see CONTRAINDICATIONS (4)]. Patients with preexisting severe neuropathy should be treated with vincristine sulfate only after careful risk-benefit assessment .

table02

Preparation and Handling

Items Required by the Pharmacy to Prepare vincristine sulfate

• vincristine sulfate Kit
• Water bath1
• Calibrated thermometer1 (0°C to 100°C)
• Calibrated electronic timer1
• Sterile venting needle or other suitable device equipped with a sterile 0.2 micron filter
• 1 mL or 3 mL sterile syringe with needle, and
• 5 mL sterile syringe with needle.

• The manufacturer will provide the water bath, calibrated thermometer, and calibrated electronic timer to the medical facility at the initial order of vincristine sulfate and will replace them every 2 years.

Preparation Instructions for vincristine sulfate (vinCRIStine sulfate LIPOSOME injection), 5 mg/31 mL (0.16 mg/mL)

• Procedures for handling and disposal of anticancer drugs should be followed [see REFERENCES (15)].

• Call [1 888 292 9617] if you have questions about the preparation of vincristine sulfate . vincristine sulfate takes approximately 60 to 90 minutes to prepare. The preparer should have dedicated uninterrupted time to prepare vincristine sulfate due to the extensive monitoring of temperature and time required for the preparation.

• Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in vincristine sulfate . The preparation steps of vincristine sulfate that involve mixing the Sodium Phosphate Injection, Sphingomyelin/Cholesterol Liposome Injection, and VinCRIStine Sulfate Injection must be done in abiological safety cabinet or by established pharmacy safety procedures for the preparation of sterile injectable formulations and hazardous drugs. However, the preparation steps that involve placement of the vial in the water bath must be done outside of the sterile area.

• Do not use with in-line filters. Do not mix with other drugs.

• Fill a water bath with water to a level of at least 8 cm (3.2 inches) measured from the bottom and maintain this minimum water level throughout the procedure. The *water bath must remain outside of the sterile area.
• Place a calibrated thermometer in the water bath to monitor water temperature and leave it in the water bath until the procedure has been completed.
• Preheat water bath to 63°C to 67°C. Maintain this water temperature until completion of the procedure using the calibrated thermometer.
• Visually inspect each vial in the vincristine sulfate Kit for particulate matter and discoloration prior to preparation, whenever solution and container permit. Do not use if a precipitate or foreign matter is present.
• Remove all the caps on the vials and swab the vials with sterile alcohol pads.
• Vent the Sodium Phosphate Injection vial with a sterile venting needle equipped with a sterile 0.2 micron filter or other suitable venting device in the biological safety cabinet. Always position venting needle point well above liquid level before adding Sphingomyelin/Cholesterol Liposome Injection and VinCRIStine Sulfate Injection.
• Withdraw 1 mL of Sphingomyelin/Cholesterol Liposome Injection.
• Inject 1 mL of Sphingomyelin/Cholesterol Liposome Injection into the Sodium Phosphate Injection vial.
• Withdraw 5 mL of VinCRIStine Sulfate Injection.
• Inject 5 mL of VinCRIStine Sulfate Injection into the Sodium Phosphate Injection vial.
• Remove the venting needle and gently invert the Sodium Phosphate Injection vial 5 times to mix. DO NOT SHAKE.
• Fit Flotation Ring around the neck of the Sodium Phosphate Injection vial.
• Confirm that the water bath temperature is at 63°C to 67°C using the calibrated thermometer. Remove the Sodium Phosphate Injection vial containing VinCRIStine Sulfate Injection, Sphingomyelin/Cholesterol Liposome Injection, and Sodium Phosphate Injection from the biological safety cabinet and place into the water bath for 10 minutes using the calibrated electronic timer. Monitor the temperature to ensure the temperature is maintained at 63°C to 67°C.
• IMMEDIATELY after placing the Sodium Phosphate Injection vial into the water bath, record the constitution start time and water temperature on the vincristine sulfate Overlabel.
• At the end of the 10 minutes, confirm that the water temperature is 63°C to 67°C using the calibrated thermometer. Remove the vial from the water bath (use tongs to prevent burns) and remove the Flotation Ring.
• Record the final constitution time and the water temperature on the vincristine sulfate Overlabel.
• Dry the exterior of the Sodium Phosphate Injection vial with a clean paper towel, affix vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) Overlabel, and gently invert 5 times to mix. DO NOT SHAKE.
• Permit the constituted vial contents to equilibrate for at least 30 minutes to controlled room temperature (15°C to 30°C, 59°F to 86°F).
• vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) contains 5 mg/31 mL (0.16 mg/mL) vincristine sulfate. ONCE PREPARED, STORE AT CONTROLLED ROOM TEMPERATURE (15°C to 30°C, 59°F to 86°F) FOR NO MORE THAN 12 HOURS.
• Swab the top of the vial now containing vincristine sulfate with a sterile alcohol pad and return the vial back into the biological safety cabinet.
• Calculate the patient's vincristine sulfate dose based on the patient's actual body surface area (BSA) and remove the volume corresponding to the patient's vincristine sulfate dose from an infusion bag containing 100 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.
• Inject the dose of vincristine sulfate into the infusion bag to result in a final volume of 100 mL.
• Complete the information required on the Infusion Bag Label and apply to the infusion bag.
• Finish administration of the diluted product within 12 hours of the initiation of vincristine sulfate preparation.
• Empty, clean, and dry the water bath after each use.
• Deviations in temperature, time, and preparation procedures may fail to ensure proper encapsulation of vincristine sulfate into the liposomes. In the event that the preparation deviates from the instructions in the above steps, the components of the kit should be discarded and a new kit should be used to prepare the dose.

• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of vincristine sulfate in adult patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of vincristine sulfate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of vincristine sulfate in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of vincristine sulfate in pediatric patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of vincristine sulfate in pediatric patients.

Contraindications

• vincristine sulfate is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.

• vincristine sulfate is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of vincristine sulfate (vinCRIStine sulfate LIPOSOME injection).

• vincristine sulfate is contraindicated for intrathecal administration.

Warnings

WARNING See full prescribing information for complete Boxed Warning. For Intravenous Use Only – Fatal if Given by Other Routes . Death has occurred with intrathecal administration. vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose prior to preparation and administration to avoid overdosage.

For Intravenous Use Only

• Fatal if Given by Other Routes. Death has occurred with intrathecal use.

Extravasation Tissue Injury

• Only administer through a secure and free-flowing venous access line. If extravasation is suspected, discontinue infusion immediately and consider local treatment measures.

Neurologic Toxicity

• Sensory and motor neuropathies are common and are cumulative. Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, hyporeflexia, areflexia, neuralgia, jaw pain, decreased vibratory sense, cranial neuropathy, ileus, burning sensation, arthralgia, myalgia, muscle spasm, or weakness, both before and during treatment. Orthostatic hypotension may occur. The risk of neurologic toxicity is greater if vincristine sulfate is administered to patients with preexisting neuromuscular disorders or when other drugs with risk of neurologic toxicity are being given. In the studies of relapsed and/or refractory adult ALL patients, Grade ≥ 3 neuropathy events occurred in 32.5% of patients. Worsening neuropathy requires dose delay, reduction, or discontinuation of vincristine sulfate .

Myelosuppression

• Monitor complete blood counts prior to each dose of vincristine sulfate . If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider vincristine sulfate dose modification or reduction as well as supportive care measures.

Tumor Lysis Syndrome

• Tumor lysis syndrome (TLS) may occur in patients with ALL receiving vincristine sulfate . Anticipate, monitor for, and manage.

Constipation and Bowel Obstruction

• Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred. vincristine sulfate can cause constipation [see ADVERSE REACTIONS (6)]. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction, and/or paralytic ileus, considering adequate dietary fiber intake, hydration, and routine use of stool softeners, such as docusate. Additional treatments, such as senna, bisacodyl, milk of magnesia, magnesium citrate, and lactulose may be considered.

Fatigue

• vincristine sulfate can cause severe fatigue. vincristine sulfate dose delay, reduction, or discontinuation may be necessary.

Hepatic Toxicity

• Fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred. Elevated levels of aspartate aminotransferase of Grade ≥3 occurred in 6-11% of patients in clinical trials. Monitor hepatic function tests. Reduce or interrupt vincristine sulfate for hepatic toxicity.

Embryofetal Toxicity

• vincristine sulfate can cause fetal harm when administered to a pregnant woman. Vincristine sulfate liposome injection was teratogenic or caused embryo-fetal death in animals. Women of childbearing potential should avoid becoming pregnant while being treated with vincristine sulfate . There are no adequate and well-controlled studies of vincristine sulfate in pregnant women and there were no reports of pregnancy in any of the clinical studies in the vincristine sulfate clinical development program. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus

Adverse Reactions

Clinical Trials Experience

• The following adverse reactions are also discussed in other sections of the labeling:

• For intravenous use only
• Extravasation tissue injury
• Peripheral Neuropathy
• Myelosuppression
• Tumor lysis syndrome
• Constipation and bowel obstruction
• Fatigue
• Hepatic toxicity

Clinical Trials Safety Experience

• Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

• Integrated Summary of Safety in Relapsed and/or Refractory Ph- Adult Acute Lymphoblastic Leukemia

• vincristine sulfate , at a dose of 2.25 mg/m2 weekly, was studied in a total of 83 patients in two trials: study 1 and study 2. Adverse reactions were observed in 100% of patients. The most common adverse reactions (>30%) were constipation (57%), nausea (52%), pyrexia (43%), fatigue (41%), peripheral neuropathy (39%), febrile neutropenia (38%), diarrhea (37%), anemia (34%), decreased appetite (33%), and insomnia (32%).

• Adverse reactions of Grade 3 or greater were reported in 96% of patients. Adverse reactions of Grade 3 or greater and occurring in ≥ 5% of patients are summarized in Table2

TABLE03

• A total of 75.9% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included febrile neutropenia (20.5%), pyrexia (13.3%), hypotension (7.2%), respiratory distress (6.0%), and cardiac arrest (6.0%).

• Dose reduction, delay, or omission occurred in 53% of patients during the treatment.

• Twenty-eight percent of patients experienced adverse reactions leading to treatment discontinuation. The most common adverse reactions that caused treatment discontinuation were peripheral neuropathy (10%), leukemia-related (7%), and tumor lysis syndrome (2%).

• Adverse reactions related to neuropathy and leading to treatment discontinuation were decreased vibratory sense, facial palsy, hyporeflexia, constipation, asthenia, fatigue, and musculoskeletal pain, each reported in at least 1 patient.

• Deaths occurred in 23% of patients in study 1. The non-leukemia related causes of deaths were brain infarct (1), intracerebral hemorrhage (2), liver failure (1), multi system organ failure (2), pneumonia and septic shock (3), respiratory failure (4), pulmonary hemorrhage (1), and sudden cardiac death (1).

Postmarketing Experience

There is limited information regarding Postmarketing Experience of vincristine sulfate in the drug label.

Drug Interactions

• No formal drug interaction studies have been conducted with vincristine sulfate . vincristine sulfate is expected to interact with drugs known to interact with non-liposomal vincristine sulfate.

• Simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included non-liposomal vincristine sulfate have been reported to reduce blood levels of phenytoin and to increase seizure activity.

CYP3A Interactions

• Vincristine sulfate, the active agent in vincristine sulfate , is a substrate for cytochrome P450 3A isozymes (CYP3A); therefore, the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's Wort).

P-glycoprotein Interactions

• Vincristine sulfate, the active agent in vincristine sulfate , is also a substrate for P-glycoprotein (P-gp). The effect of concomitant use of potent P-gp inhibitors or inducers has not been investigated; it is likely that these agents will alter the pharmacokinetics or pharmacodynamics of vincristine sulfate . Therefore the concomitant use of potent P-gp inhibitors or inducers should be avoided.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category D

• Based on its mechanism of action and findings from animal studies, vincristine sulfate can cause fetal harm when administered to pregnant women.

• If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. In an embryofetal developmental study, pregnant rats were administered vincristine sulfate liposome injection intravenously during the period of organogenesis at vincristine sulfate doses of 0.022 to 0.09 mg/kg/day. Drug-related adverse effects included fetal malformations (skeletal and visceral), decreases in fetal weights, increased numbers of early resorptions and post-implantation losses, and decreased maternal body weights Malformations were observed at doses ≥ 0.044 mg/kg/day in animals at systemic exposures approximately 20-40% of those reported in patients at the recommended dose.

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of vincristine sulfate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of vincristine sulfate during labor and delivery.

Nursing Mothers

• It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Pediatric Use

• The safety and effectiveness of vincristine sulfate in pediatric patients have not been established.

Geriatic Use

• Safety and effectiveness in elderly individuals have not been established. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Gender

There is no FDA guidance on the use of vincristine sulfate with respect to specific gender populations.

Race

There is no FDA guidance on the use of vincristine sulfate with respect to specific racial populations.

Renal Impairment

• The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine sulfate has not been evaluated.

Hepatic Impairment

• Non-liposomal vincristine sulfate is excreted primarily by the liver. The influence of severe hepatic impairment on the safety and efficacy of vincristine sulfate has not been evaluated.

• The pharmacokinetics of vincristine sulfate was evaluated in patients with moderate hepatic dysfunction (Child-Pugh B) secondary to melanoma liver metastases. The dose-adjusted maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) of vincristine sulfate in patients with moderate hepatic impairment was comparable to the Cmax and AUC of patients with ALL who had otherwise normal hepatic function.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of vincristine sulfate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of vincristine sulfate in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

• Intravenous

Monitoring

There is limited information regarding Monitoring of vincristine sulfate in the drug label.

• Description

IV Compatibility

There is limited information regarding IV Compatibility of vincristine sulfate in the drug label.

Overdosage

• When vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) was administered at a dose of 2.4 mg/m2, severe toxicities including motor neuropathy of Grade 3, grand mal seizure of Grade 4, and elevated aspartate aminotransferase and hyperbilirubinemia of Grade 4 were reported in 1 patient each. There is no known antidote for overdosage

Pharmacology

There is limited information regarding Vincristine liposome Pharmacology in the drug label.

Mechanism of Action

• vincristine sulfate is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate. Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting in altered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus, preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.

Structure

• vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) is vincristine encapsulated in sphingomyelin/cholesterol liposomes for intravenous administration.

• The active ingredient in vincristine sulfate is vincristine sulfate. Vincristine sulfate is a vinca alkaloid isolated as a 1:1 sulfate salt from the periwinkle plant (Catharanthus roseus). It is a hygroscopic, white to slightly yellowish crystalline powder that is soluble in water. It has a molecular weight of 923.04 (salt form) / 824.98 (base form) and a molecular formula of C46H56N4O10 • H2SO4. The chemical name for vincristine sulfate is 22-oxovincaleukoblastine and it has the following chemical structure:

This image is provided by the National Library of Medicine.

• Vincristine is encapsulated in a Sphingomyelin/Cholesterol liposome. The lipid components in the liposome are sphingomyelin and cholesterol at a molar ratio of approximately 60:40 (mol:mol).

• After preparation, each vial of vincristine sulfate contains 5 mg vincristine sulfate, 500 mg mannitol, 73.5 mg sphingomyelin, 29.5 mg cholesterol, 36 mg sodium citrate, 38 mg citric acid, 355 mg sodium phosphate, and 225 mg sodium chloride.

• vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) appears as a white to off-white, translucent suspension, essentially free of visible foreign matter and aggregates, comprised of sphingomyelin/cholesterol liposomes, with an approximate liposome mean diameter of 100 nm. Greater than 95% of the drug is encapsulated in the liposomes.

• The vincristine sulfate Kit component vials for the preparation of vincristine sulfate (vinCRIStine sulfate LIPOSOME injection) include:

• VinCRIStine Sulfate Injection, USP (5 mg/5 mL). Each VinCRIStine Sulfate Injection vial consists of 5 mg/5 mL vincristine sulfate (which is equivalent to 4.5 mg/5 mL vincristine free base) and 500 mg/5 mL mannitol.
• Sphingomyelin/Cholesterol Liposome Injection (103 mg/mL). Each Sphingomyelin/Cholesterol Liposome Injection vial consists of 73.5 mg/mL sphingomyelin, 29.5 mg/mL cholesterol, 33.6 mg/mL citric acid, 35.4 mg/mL sodium citrate, and not more than 0.1% ethanol.
• Sodium Phosphate Injection (355 mg/25 mL). Each Sodium Phosphate Injection vial consists of 355 mg/25 mL dibasic sodium phosphate and 225 mg/25 mL sodium chloride.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of vincristine sulfate in the drug label.

Pharmacokinetics

• The plasma pharmacokinetics of vincristine sulfate was investigated in 13 adult patients with relapsed ALL who received a vincristine sulfate dose of 2.25 mg/m2 administered as a 1-hour intravenous infusion. The calculated pharmacokinetic parameters for total plasma vincristine sulfate are given in TABLE 3. The vincristine sulfate levels reported in TABLE 3 reflect liposome-encapsulated drug that may not be immediately bioavailable and may not be directly comparable to plasma levels of vincristine sulfate after administration of non-liposomal vincristine sulfate, which is immediately bioavailable.

table04

• The plasma clearance (CL) of vincristine sulfate is slow, 345 mL/h, at a dose of 2.25 mg/m2. This is in comparison to the rapid clearance of non-liposomal vincristine sulfate at 189 mL/min/m2 (11,340 mL/h). The slow clearance of vincristine sulfate contributes to a much higher AUC for vincristine sulfate relative to non-liposomal vincristine sulfate.

• Following intravenous administration of vincristine sulfate , urinary excretion was a minor route of elimination for vincristine sulfate and its metabolite. Less than 8% of the administered vincristine sulfate dose was eliminated in urine over a 96-hour observation period, which is similar to the urinary excretion of non-liposomal vincristine sulfate. Following non-liposomal vincristine sulfate infusion, the main route of vincristine sulfate excretion was the fecal route, accounting for 69% of the administered dose over 72 hours.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

• No carcinogenicity studies have been conducted with vincristine sulfate or non-liposomal vincristine sulfate. Based on the mechanism of action and genotoxicity findings in nonclinical studies conducted with non-liposomal vincristine sulfate, vincristine sulfate may be carcinogenic.

• No genotoxicity studies have been conducted with vincristine sulfate . Non-liposomal vincristine was genotoxic in some in vitro and in vivo studies.

• The single- and repeat-dose animal toxicology study results indicate that vincristine sulfate can impair male fertility, consistent with the literature on non-liposomal vincristine sulfate. Administration of vincristine liposome injection causes testicular degeneration and atrophy, and epididymal aspermia in rats.

• Gonadal dysfunction has been reported in both male and female post-pubertal patients who received multi-agent chemotherapy including non-liposomal vincristine sulfate. The degree to which testicular or ovarian functions are affected is age-, dose-, and agent-dependent. Recovery may occur in some but not all patients.

Animal Toxicology and/or Pharmacology

• In a repeat-dose comparative toxicology study in rats, vincristine sulfate liposome injection or non-liposomal vincristine sulfate was administered to animals intravenously once per week for 6 weeks. Clinical signs of toxicity consistent with neurotoxicity were greater with vincristine sulfate liposome injection than with non-liposomal vincristine sulfate at equal vincristine sulfate doses of 2 mg/m2/week and included uncoordinated movements, weakness, reduced muscle tone, and limited usage of the limbs. Neurological testing indicated drug-induced peripheral neurotoxicity with both drugs. Based on the histopathology examination after 6 weekly doses, vincristine sulfate liposome injection induced greater peripheral neurotoxicity (nerve fiber degeneration) and secondary skeletal muscle atrophy than the equal dose of non-liposomal vincristine sulfate. In a separate tissue distribution study in rats, administration of 2 mg/m2 of intravenous liposomal or non-liposomal vincristine sulfate showed greater accumulation of vincristine sulfate in sciatic and tibial nerves (as well as the lymph nodes, spleen, and bone marrow) of the animals following vincristine sulfate liposome injection.

Clinical Studies

Acute Lymphoblastic Leukemia

• vincristine sulfate was studied in an international, open-label, multi-center, single-arm trial (Study 1). Eligible patients were 18 years of age or older with Philadelphia chromosome negative ALL in second or greater relapse or whose disease progressed after two or greater treatment lines of anti-leukemia therapy. Patients had to have achieved a complete remission (CR) to at least one prior anti-leukemia chemotherapy, defined by a leukemia-free interval of equal or more than 90 days. Patients were not eligible for immediate hematopoietic stem cell transplantation (HSCT) at the time of screening and enrollment.

• Patients received intravenous vincristine sulfate monotherapy at 2.25 mg/m2 over 60 minutes every 7 days. Concomitant corticosteroids were not permitted beyond Day 5.

• The treated population included 65 patients who received at least 1 dose of vincristine sulfate . All of the treated patients had received prior vincristine sulfate and 80% had evidence of residual neuropathy at study baseline. Among treated patients, 51% were male, 86% were white, 45% were under 30 years of age, 11% were age 65 or older, 48% had undergone prior HSCT, 51% had received 3 or more prior therapies, and 45% were refractory to their immediate prior therapy. Disease characteristics were 85% precursor B-cell ALL and 15% precursor T-cell ALL. In addition, 22 of 65 (34%) treated patients did not receive asparaginase products prior to enrollment. Efficacy results are shown in TABLE 4.

table05

How Supplied

• The vincristine sulfate Kit (NDC # 20536-322-01) contains:

• Vial containing VinCRIStine Sulfate Injection, USP 5 mg/5 mL (1 mg/mL) – NDC # 20536-323-01
• Vial containing Sphingomyelin/Cholesterol Liposome Injection 103 mg/mL – NDC # 20536-324-01
• Vial containing Sodium Phosphate Injection 355 mg/25 mL (14.2 mg/mL) – NDC # 20536-325-01
• Flotation Ring
• Overlabel for Sodium Phosphate Injection vial containing constituted vincristine sulfate (vinCRIStine sulfate LIPOSOME injection), 5 mg/31 mL (0.16 mg/mL)
• Infusion Bag Label

16.1 Storage

• Store the vincristine sulfate Kit in the refrigerator at 2°C to 8°C – Do Not Freeze

Storage

There is limited information regarding Vincristine liposome Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Vincristine liposome |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Vincristine liposome |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

• Physicians are advised to discuss the following with patients prior to treatment with vincristine sulfate :

• Extravasation Tissue Injury: Advise patients to report immediately any burning or local irritation during or after the infusion [see WARNINGS AND PRECAUTIONS (5.2)].

• Ability to Drive or Operate Machinery or Impairment of Mental Ability: vincristine sulfate may cause fatigue and symptoms of peripheral neuropathy. Advise patients not to drive or operate machinery if they experience any of these symptoms [see WARNINGS AND PRECAUTIONS (5.3, 5.7)].

• Gastrointestinal/Constipation: Patients receiving vincristine sulfate may experience constipation. Advise patients how to avoid constipation by a diet high in bulk fiber, fruits and vegetables, and adequate fluid intake as well as use of a stool softener, such as docusate. Instruct patients to seek medical advice if they experience symptoms of constipation such bowel movement infrequency, abdominal pain, bloating, diarrhea, nausea, or vomiting [see WARNINGS AND PRECAUTIONS (5.6)].

• Pregnancy/Nursing: Advise patients to use effective contraceptive measures to prevent pregnancy during treatment with vincristine sulfate [see WARNINGS AND PRECAUTIONS (5.9)]. Instruct patients to report pregnancy to their physicians immediately. Advise patients that they should not receive vincristine sulfate while pregnant or breastfeeding. If a patient wishes to re-start breastfeeding after treatment, she should be advised to discuss the appropriate timing with her physician [see USE IN SPECIFIC POPULATIONS (8.3)].

• Concomitant Medications: Advise patients to speak with their physicians about any other medication they are currently taking [see DRUG INTERACTIONS (7)].

• Peripheral Neuropathy: Advise patients to contact their physicians if they experience new or worsening symptoms of peripheral neuropathy such as tingling, numbness, pain, a burning feeling in the feet or hands, or weakness in the feet or hands [see WARNINGS AND PRECAUTIONS (5.3)].

• Other: Instruct patients to notify their physicians if they experience fever, productive cough, or decreased appetite

Precautions with Alcohol

• Alcohol-vincristine sulfate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• ®

Look-Alike Drug Names

There is limited information regarding Vincristine liposome Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Vincristine liposome
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Vincristine liposome
 |Label Name=vincristine sulfate 06.png

}}

{{#subobject:

 |Label Page=Vincristine liposome
 |Label Name=vincristine sulfate 07.png

}}

{{#subobject:

 |Label Page=Vincristine liposome
 |Label Name=vincristine sulfate 08.png

}}

{{#subobject:

 |Label Page=Vincristine liposome
 |Label Name=vincristine sulfate 09.png

}}

{{#subobject:

 |Label Page=Vincristine liposome
 |Label Name=vincristine sulfate 10.png

}} [[Category:Chemotherapeutic agents]]